A

argenx

Develops antibody-based therapies for autoimmune diseases

Global Pricing Director - Germany & Developed Markets

Full-TimeUpdated on 10/22/2026
No salary listed
Expert
Bachelor's
Remote in Belgium+1 moreMore locations: Remote in Switzerland
RemoteRegular international travel required.
Finance & Banking

About the job

Requirements
  • Deep expertise in global pharmaceutical pricing, market access, and reimbursement strategy, including experience across health technology assessment markets.
  • Ability to develop and execute launch pricing strategies for specialty medicines, rare diseases, and innovative products.
  • Strong understanding of International Reference Pricing, launch sequencing, pricing governance, and global market dynamics.
  • Ability to connect long-term strategy to practical execution and measurable outcomes.
  • Ability to influence senior leaders and drive alignment in a matrixed global organization.
  • Strong analytical capability, including using data, scenarios, and structured decision-making to inform pricing recommendations.
  • Communication and presentation skills, including translating complex pricing concepts into clear, actionable guidance.
  • Ability to operate effectively in a scientific, dynamic, fast-moving environment with ambiguity and change.
  • Project management skills, including proactive planning, prioritization, risk management, and follow-through.
  • Ability to build trust across cultures, functions, and geographies.
  • At least 10 years of relevant biotechnology, pharmaceutical, or healthcare industry experience.
  • At least 8 years of global pricing, market access, and reimbursement experience.
  • Demonstrated experience leading or materially contributing to pricing strategy for global product launches.
  • Proven track record of influencing strategic decisions and delivering pricing recommendations across major markets.
  • Fluent English.
Responsibilities
  • Lead development of global pricing strategies for upcoming launches, pipeline assets, and lifecycle opportunities across indications, focusing on Germany and developed markets, including large European markets, Canada, and Australia.
  • Define launch pricing frameworks, price corridors, and strategic guidance to support long-term value, sustainable reimbursement, and patient access.
  • Translate global pricing strategy into actionable plans, pricing policies, and implementation guidance for regional and country teams.
  • Drive alignment, clarify trade-offs, and ensure pricing decisions are embedded in launch readiness and execution plans.
  • Partner with country teams to align local pricing and reimbursement strategies with global pricing principles and policies while reflecting market-specific requirements.
  • Assess and mitigate International Reference Pricing risks, launch sequencing implications, and cross-market price interdependencies.
  • Collaborate with finance and forecasting teams to develop pricing assumptions, scenario analyses, and long-term revenue implications for launches and lifecycle decisions.
  • Contribute to business cases for launch and reimbursement decisions, market entry decisions, and access strategies, considering price sustainability, accessible patient populations, and external pricing dynamics.
  • Monitor external pricing, reimbursement, policy, and competitive environments to identify risks and opportunities affecting launch success and long-term pricing sustainability.
  • Partner with the Global Access Community on global pricing governance to ensure timely, transparent, and well-documented pricing decisions across relevant leadership forums.
  • Partner with the Pricing Community to develop and maintain pricing tools, frameworks, guidance, and ways of working that strengthen pricing capability and consistency.
  • Manage and provide strategic direction to external vendors, consultants, and partners, including expectations, project plans, deliverables, timelines, and quality standards.
  • Build cross-functional relationships and serve as a pricing advisor to global, regional, and country leaders.
  • Contribute to pricing capability development and a collaborative team culture focused on execution, innovation, and patient impact.
Desired Qualifications
  • Strong understanding of the German market access environment.
  • Experience in rare disease, specialty care, immunology, or other highly specialized therapeutic areas.
  • Advanced graduate-level training in natural sciences, medicine, business, finance, health economics, public policy, or a related field.
  • Additional languages.

About the company

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
CNBC TV18
Oct 16th, 2026
Mankind Pharma to buy 70% stake in cancer therapy firm ACTx for ₹511 crore.

Mankind Pharma to buy 70% stake in cancer therapy firm ACTx for ₹511 crore. October 16, 2026 | 11:02 IST AI Summary Mankind Pharma has agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics for ₹511.18 crore, marking its entry into next-generation cancer cell therapies like armed CAR-T treatments. Mankind Pharma has agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for €48 million (₹511.18 crore), marking its entry into next-generation cancer cell therapies. The acquisition will be made through Mankind Pharma (Netherlands) B.V., a wholly owned subsidiary that has signed a definitive agreement for the deal. The consideration will be paid entirely in cash in instalments. Completion is subject to any regulatory approvals required under local laws. Mankind Pharma's board, which met on Thursday, also approved an additional investment of up to €45 million in the Dutch subsidiary. The investment will be made in one or more tranches, taking the total approved investment limit to €50 million, including the €5 million sanctioned earlier. The subsidiary was incorporated on August 13, 2026, to hold investments in research and development assets and pursue business development in niche therapies through joint ventures or strategic stakes. It has reported no turnover since its recent incorporation. What ACTx does ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies, known as "armed" CAR-T, to treat cancer. Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer. The company is also exploring approaches such as generating CAR-T cells inside the body, known as in vivo CAR-T. CAR-T therapy modifies a patient's immune cells to recognise and attack cancer cells. While the treatment has transformed care for some blood cancers, patients can relapse because the modified cells may not persist or may become exhausted, while cancer cells can develop resistance. Solid tumours pose additional challenges because CAR-T cells can struggle to penetrate tumours and function in their hostile environments. Armed CAR-T therapies are designed with additional biological payloads to strengthen their anti-tumour activity and potentially deliver deeper, more durable responses. Targeting multiple cancer antigens may also help prevent cancer cells from evading treatment. ACTx is headquartered in Belgium, has operations in the Netherlands and conducts research and pre-clinical work in Pittsburgh, the US. Its research and development teams are based in the US and Europe. Its founders include Paul Stoffels, board chair and former chief executive of Galapagos and former chief scientific officer of Johnson & Johnson; John Mellors, chief scientific officer and a professor of medicine at the University of Pittsburgh who previously served as a senior vice-president at Galapagos; and Peter Verhaeghe, former chair of argenx. Mankind bets on innovation-led growth Arjun Juneja, chief operating officer of Mankind Pharma, said the investment marked the first step towards building a global pipeline of breakthrough therapies. "Innovation will be one of the defining growth engines for Mankind over the coming decades," Juneja said, adding that the company aims to make such therapies more accessible to patients in India and worldwide over the long term. Stoffels said next-generation CAR-T therapies could reach more patients if they became more powerful and durable. ACTx now had the assets, team and backing from Mankind to pursue that goal, he said. Mankind said its investment in the Dutch subsidiary would qualify as a related-party transaction but would be exempt under Regulation 23(5) of SEBI's listing regulations because the subsidiary is wholly owned. The subsidiary's investment in ACTx would not constitute a related-party transaction. The deal will not alter Mankind's shareholding in its Dutch subsidiary. Mankind describes itself as one of India's largest pharmaceutical companies, with a field force of more than 18,500 and a reach of over five lakh doctors. It operates 32 manufacturing facilities in India and seven dedicated research and development facilities staffed by more than 740 scientists. Mankind Pharma shares closed at ₹2,347.60 on the NSE on Thursday, up 0.54%.

Business Insider
Oct 8th, 2026
Argenx Se (ARGX) receives a Buy from RBC Capital.

Argenx Se (ARGX) receives a Buy from RBC Capital. Oct. 8, 2026, 09:47 PM In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of $1,100.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 34.62% success rate. Issi covers the Healthcare sector, focusing on stocks such as Amgen, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1,182.58 average price target. Based on Argenx Se's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.82 billion and a net profit of $838.82 million. In comparison, last year the company earned a revenue of $947.96 million and had a net profit of $245.36 million Read More on ARGX:

Yahoo Finance
Oct 8th, 2026
Argenx shares drop 15% as Vyvgart fails Sjögren's trial despite celiac drug success

Argenx shares dropped 15% on Thursday after the Dutch biotech announced its blockbuster drug Vyvgart failed to help patients with Sjögren's disease. An independent monitoring board recommended ending the Phase 3 study "for futility" following an interim analysis. The timing surprised analysts, who weren't expecting results until the second half of 2027. Success in Sjögren's could have generated up to $1.4 billion in peak sales for that indication alone. A separate announcement of successful Phase 2 research into a celiac disease drug failed to offset investor concerns. Argenx acquired the medicine, FB102, through a $2.2 billion takeover of Forte Biosciences this year. TD Securities analyst Yaron Werber models $988 million in peak sales for the celiac drug. Despite the setback, Argenx maintains a market cap of around $50 billion. Vyvgart sales reached $1.5 billion in the second quarter alone.

Yahoo Finance
Oct 5th, 2026
10 analysts set Argenx price targets above $1,200 as biotech's revenue surges 60%

Argenx, a biopharmaceutical company with a market capitalisation near $60 billion, has caught the attention of Wall Street analysts. Ten analysts predict the biotech stock will reach at least $1,200 over the next 12 months, up from around $919 as of 2 October 2026. Wells Fargo and UBS set the highest price targets at $1,415 and $1,400 respectively, representing potential gains exceeding 50%. The average price target amongst 21 analysts stands at approximately $1,182, suggesting 29% upside. All but one analyst recommends buying the stock. Argenx's optimism stems from strong performance, delivering $1.5 billion in global product net sales last quarter, up 60% year over year. Its flagship drugs Vyvgart and Vyvgart Hytrulo drive growth, with additional approvals for autoimmune diseases potentially forthcoming.

ReachMD
Sep 30th, 2026
argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026.

argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.